Literature DB >> 17944486

Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope.

Brian O'Nuallain1, Amy Allen, Demet Ataman, Deborah T Weiss, Alan Solomon, Jonathan S Wall.   

Abstract

Amyloid fibrils and partially unfolded intermediates can be distinguished serologically from native amyloidogenic precursor proteins or peptides. In this regard, we previously had reported that mAb 11-1F4, generated by immunizing mice with a thermally denatured variable domain (VL) fragment of the human kappa4 Bence Jones protein Len, bound to a non-native conformational epitope located within the N-terminal 18 residues of fibrillar, as well as partially denatured, Ig light chains (O'Nuallain, B., et al. (2006) Biochemistry 46, 1240-1247). To define further the antibody binding site, we used random peptide phage display and epitope mapping of VL Len using wild-type and alanine-mutated Len peptides where it was shown that the antibody epitope was reliant on up to 10 of the first 15 residues of protein Len. Comparison of Vkappa and Vlambda N-terminal germline consensus sequences with protein Len and 11-1F4-binding phages indicated that this antibody's cross-reactivity with light chains was related to an invariant proline at position(s) 7 and/or 8, bulky hydrophobic residues at positions 11 and 13, and additionally, to the ability to accommodate amino acid diversity at positions 1-4. Sequence alignments of the phage peptides revealed a central proline, often flanked by aromatic residues. Taken together, these results have provided evidence for the structural basis of the specificity of 11-1F4 for both kappa and lambda light chain fibrils. We posit that the associated binding site involves a rare type VI beta-turn or touch-turn that is anchored by a cis-proline residue. The identification of an 11-1F4-related mimotope should facilitate development of pan-light chain fibril-reactive antibodies that could be used in the diagnosis and treatment of patients with AL amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17944486      PMCID: PMC2677975          DOI: 10.1021/bi701255m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  54 in total

1.  Mimotopes: realization of an unlikely concept.

Authors:  R H Meloen; W C Puijk; J W Slootstra
Journal:  J Mol Recognit       Date:  2000 Nov-Dec       Impact factor: 2.137

Review 2.  Combinatorial alanine-scanning.

Authors:  K L Morrison; G A Weiss
Journal:  Curr Opin Chem Biol       Date:  2001-06       Impact factor: 8.822

Review 3.  Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics.

Authors:  Lin-Fa Wang; Meng Yu
Journal:  Curr Drug Targets       Date:  2004-01       Impact factor: 3.465

4.  The cis-Pro touch-turn: a rare motif preferred at functional sites.

Authors:  Lizbeth L Videau; W Bryan Arendall; Jane S Richardson
Journal:  Proteins       Date:  2004-08-01

Review 5.  Structures for amyloid fibrils.

Authors:  O Sumner Makin; Louise C Serpell
Journal:  FEBS J       Date:  2005-12       Impact factor: 5.542

6.  Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera.

Authors:  Brian O'Nuallain; Rudi Hrncic; Jonathan S Wall; Deborah T Weiss; Alan Solomon
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

7.  Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants.

Authors:  G Goldsteins; H Persson; K Andersson; A Olofsson; I Dacklin; A Edvinsson; M J Saraiva; E Lundgren
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 8.  Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.

Authors:  Raymond L Comenzo
Journal:  Contrib Nephrol       Date:  2007       Impact factor: 1.580

Review 9.  Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis.

Authors:  Per Westermark; Merrill D Benson; Joel N Buxbaum; Alan S Cohen; Blas Frangione; Shu-Ichi Ikeda; Colin L Masters; Giampaolo Merlini; Maria J Saraiva; Jean D Sipe
Journal:  Amyloid       Date:  2005-03       Impact factor: 7.141

10.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

View more
  12 in total

1.  Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.

Authors:  Marybeth Camboni; Chiou-Miin Wang; Carlos Miranda; Jung Hae Yoon; Rui Xu; Deborah Zygmunt; Brian K Kaspar; Paul T Martin
Journal:  Neurobiol Dis       Date:  2013-09-08       Impact factor: 5.996

2.  Development and evaluation of agents for targeting visceral amyloid.

Authors:  Jonathan S Wall; Alan Solomon; Stephen J Kennel
Journal:  Tijdschr Nucl Geneeskd       Date:  2011-12

3.  Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chains.

Authors:  Sharad P Adekar; Igor Klyubin; Sally Macy; Michael J Rowan; Alan Solomon; Scott K Dessain; Brian O'Nuallain
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

Review 4.  Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

5.  Radioimmunodetection of amyloid deposits in patients with AL amyloidosis.

Authors:  Jonathan S Wall; Stephen J Kennel; Alan C Stuckey; Misty J Long; David W Townsend; Gary T Smith; Karen J Wells; Yitong Fu; Michael G Stabin; Deborah T Weiss; Alan Solomon
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

6.  Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis.

Authors:  Jonathan S Wall; James S Foster; Emily B Martin; Stephen J Kennel
Journal:  Pharm Pat Anal       Date:  2017-08-21

7.  Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo.

Authors:  Vaibhav Tiwari; Jian Liu; Tibor Valyi-Nagy; Deepak Shukla
Journal:  J Biol Chem       Date:  2011-05-19       Impact factor: 5.157

8.  A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.

Authors:  Brian O'Nuallain; Igor Klyubin; Jessica M Mc Donald; James S Foster; Alfred Welzel; Andrew Barry; Richard K Dykoski; James P Cleary; Martijn F B G Gebbink; Michael J Rowan; Dominic M Walsh
Journal:  J Neurochem       Date:  2011-08-22       Impact factor: 5.372

9.  Structure and energetic basis of overrepresented λ light chain in systemic light chain amyloidosis patients.

Authors:  Jun Zhao; Baohong Zhang; Jianwei Zhu; Ruth Nussinov; Buyong Ma
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-12-12       Impact factor: 5.187

10.  Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy.

Authors:  Jonathan S Wall; Angela D Williams; James S Foster; Tina Richey; Alan Stuckey; Sallie Macy; Craig Wooliver; Shawn R Campagna; Eric D Tague; Abigail T Farmer; Ronald H Lands; Emily B Martin; R Eric Heidel; Stephen J Kennel
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.